Brepocitinib Skin Outcomes Published in JAMA Dermatology
Analysis based on 7 articles · First reported Aug 26, 2026 · Last updated Aug 26, 2026
The publication of positive skin-specific outcomes from the VALOR trial strengthens the clinical evidence for brepocitinib in dermatomyositis, potentially accelerating its regulatory approval and market adoption. This is likely to positively impact Priovant Therapeutics and its parent Roivant Sciences, as it de-risks the asset and supports its commercial potential in a disease with high unmet need.
Priovant Therapeutics announced the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults with dermatomyositis. The publication highlights rapid and durable improvements in cutaneous disease activity, itch, and skin-related quality of life for brepocitinib 30 mg compared to placebo. Notably, among patients with moderate-to-severe skin disease at baseline, nearly half achieved remission-level outcomes by Week 52, with 46% achieving clear or almost clear skin on the IGA and 44% achieving functional skin remission on the CDASI-A, more than double the placebo rates. The results complement the primary efficacy and safety findings previously published in the The New England Journal of Medicine and reinforce brepocitinib's potential as an important treatment for dermatomyositis skin manifestations. The VALOR trial enrolled 241 subjects across 90 sites, and brepocitinib 30 mg demonstrated statistically significant improvements on all nine key secondary endpoints, including measures of muscle strength, skin disease activity, functional disability, and steroid tapering. The safety profile was consistent with known JAK inhibitor safety, with no new signals identified. Priovant Therapeutics is a Roivant company, and brepocitinib is also being evaluated in Phase 3 programs for non-infectious uveitis and cutaneous sarcoidosis, and a Phase 2b/3 program for lichen planopilaris.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard